Table 1 | EC50sa of GRFT and various entry inhibitors..

Inhibitor	Griffithsin (nM)		Dose reduction	P<0.05	Inhibitor		Dose reduction	P<0.05
Inhibitor	Alone	Combi	Dose reduction	P<0.05	Alone	Combi	Dose reduction	P<0.05
b12mAb (μg/ml)	0.057 ± 0.015	0.019 ± 0.006	3.1	0.058	0.074 ± 0.031	0.038 ± 0.013	1.9	0.323
2F5 mAb (μg/ml)	0.094 ± 0.017	0.024 ± 0.004	4.0	0.016	3.6 ± 1.6	1.2 ± 0.2	3.0	0.200
2G12 mAb (μg/ml)	0.082 ± 0.014	0.070 ± 0.000	1.2	0.487	>100	>100
AMD3100 (μM)	0.11 ± 0.03	0.040 ± 0.020	2.8	0.111	4.1 ± 3.2	0.50 ± 0.24	8.1	0.332
BanLec (nM)	0.10 ± 0.01	0.043 ± 0.013	2.4	0.012	0.54 ± 0.17	0.15 ± 0.05	3.6	0.073
T20 (μM)	0.10 ± 0.02	0.032 ± 0.001	3.2	0.039	0.098 ± 0.059	0.029 ± 0.011	3.4	0.293
PRO2000 (μM)	0.088 ± 0.008	0.047 ± 0.004	1.9	0.009	0.084 ± 0.003	0.048 ± 0.004	1.8	0.003

^aMean EC₅₀s ± SEM up to 4 independent experiments
P<0.05 (unpaired T-test), compared to single drug treatment

Table 1: EC₅₀s^a of GRFT and various entry inhibitors, alone and in combination, in the HIV-1 induced cell-cell assay (giant cell assay).

Goto home»